关节镜下肩袖修复术后向盂肱关节注射皮质类固醇安全吗
这项随机对照试验纳入80例小到中等肩袖撕裂行关节镜下修复的患者,术后8周分别向盂肱关节注射曲安奈德40 mg加利多卡因1.5 mL或生理盐水。注射组术后3个月前屈、外旋活动度及ASES评分更优、疼痛评分更低,但6个月后差异消失;12个月MRI再撕裂率两组无显著差异。结论认为该注射不增加再撕裂风险,是早期改善活动度和临床评分的有效安全方法。
要点
- 术后8周盂肱关节注射曲安奈德40 mg加利多卡因1.5 mL不增加12个月MRI再撕裂风险。
- 注射组术后3个月前屈、侧方外旋、外展外旋活动度及ASES评分优于对照组,疼痛评分更低。
- 术后6个月后活动度和ASES评分两组无显著差异。
核心结论
- 肩袖修复术后关节内注射皮质类固醇不增加再撕裂风险,是早期增加活动度(前屈、外旋)和改善临床评分(ASES)的有效安全治疗方法。
研究设计与样本
- 随机对照试验,证据等级1;2011年3月至2014年4月纳入80例小到中等肩袖撕裂行关节镜下肩袖修复的患者,随机分为两组各40例。
主要发现
- 平均随访25.7个月;术后3个月注射组前屈(P=0.05)、侧方外旋(P=0.05)、外展外旋(P=0.04)活动度显著高于对照组,背后内旋两组无显著差异(P=0.65)。
- 术后3个月注射组疼痛视觉模拟评分显著低于对照组(P=0.02),ASES评分注射组68.90 vs 对照组60.28(P=0.02)。
- 术后6个月后活动度和ASES评分两组无显著差异(注射组77.80 vs 对照组75.88,P=0.33)。
- 12个月MRI按Sugaya分类IV和V级判定再撕裂共7例(8.8%):注射组3例(7.5%),对照组4例(10%);两组再撕裂率无统计学显著差异(P=0.69)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Injection of intra-articular corticosteroids is effective for improving the recovery of range of motion (ROM) and pain in various conditions of the shoulder but its use is limited after rotator cuff repair owing to concern over the possible harmful effects of steroids on the repaired tendon. PURPOSE: To evaluate the effect of intra-articular corticosteroid injections on the clinical outcomes and cuff integrity of patients after rotator cuff repair. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: Between March 2011 and April 2014, 80 patients with a small- to medium-sized rotator cuff tear were enrolled in this study and underwent arthroscopic rotator cuff repair. Forty patients received an injection of triamcinolone (40 mg) and lidocaine (1.5 mL) into the glenohumeral joint 8 weeks after surgery (group 1), while the remaining 40 patients received normal saline injection (group 2). Outcome measures-including ROM, American Shoulder and Elbow Surgeons (ASES) score, Constant score, pain visual analog scale, and Simple Shoulder Test score-were evaluated at 3, 6, and 12 months after surgery and at the last follow-up. The integrity of the repaired tendon was evaluated by magnetic resonance imaging (MRI) and classified per Sugaya classification at 8 weeks (before injection) and 12 months after surgery. RESULTS: The mean follow-up period was 25.7 months. At 3 months postoperatively, patients in group 1 had a significantly higher ROM with respect to forward flexion ( P = .05), external rotation at the side ( P = .05), and external rotation at abduction ( P = .04) as compared with group 2, whereas no significant difference was noted between the groups for internal rotation behind the back ( P = .65). Patients in group 1 had significantly lower visual analog scale pain scores ( P = .02) and higher ASES scores (group 1, 68.90; group 2, 60.28; P = .02) at 3-month follow-up. However, there was no significant difference after 6 months with respect to ROM and ASES scores (group 1, 77.80; group 2, 75.88; P = .33). Retears (Sugaya classification IV and V) were determined by MRI at 12 months and observed in a total of 7 patients (8.8%): 3 from group 1 (7.5%) and 4 from group 2 (10%). No retears were observed on MRI in the remaining 73 patients (91.2%): 37 patients from group 1 and 36 patients from group 2. There was no statistically significant difference in rate of retears between groups ( P = .69). CONCLUSION: Intra-articular injection of corticosteroids after rotator cuff repair does not increase the risk of retears and is thus an effective and safe treatment method for increasing ROM (forward flexion, external rotation) and improving clinical score (ASES) during the early postoperative period of patients undergoing rotator cuff repair.
引用
- Kim YS, Jin HK, Lee HJ, et al. Is It Safe to Inject Corticosteroids Into the Glenohumeral Joint After Arthroscopic Rotator Cuff Repair? Am J Sports Med. 2019. PMID: 31084488. doi:10.1177/0363546519843910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。